The translation of stem cell therapies begins with a well-characterized and thoroughly documented starting cell source. REPROCELL’s StemRNA™ Clinical iPSC Seed Stock Clones offer cell therapy developers streamlined starting material that provides a gateway into early-stage clinical development. By combining regulatory alignment with ethical sourcing and footprint-free mRNA reprogramming, REPROCELL now offers various male and female, ready-to-use, clinical-grade iPSC lines manufactured in our facilities, in the U.S. and Japan. [Read more…]
Japan Moves Toward Permitting Fertilized Embryo Research Using iPSC-Derived Eggs and Sperm
A Japanese government bioethics panel has given the green light to a controversial but closely regulated area of research: the creation of human embryos using lab-generated sperm and eggs derived from pluripotent stem cells, including induced pluripotent stem (iPS) cells. The panel’s recommendation allows this practice strictly for scientific research focused on infertility and genetic diseases—not for reproductive purposes. [Read more…]
Vita Therapeutics and I Peace announced a development program to generate iPS- derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells
Palo Alto, CA, July 10, 2025 – Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy.
GMP-grade iPS cells will be modified with proprietary, licensed gene editing technology to make a base platform hypoimmune line where Class I and II HLA genes that determine rejection have been depleted. These hypoimmune lines can be further customized in I Peace cGMP facilities. [Read more…]
Burgeoning Number of iPSC Therapies To Be Tested in Clinical Trials
Therapeutic applications of induced pluripotent stem cells (iPSCs) have surged in recent years. Since the creation of human iPSCs in 2007, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2014. From 2014 to present, additional trials and physician-led studies employing human iPSC-derived cell types have been initiated across multiple geographies worldwide. [Read more…]
Pioneering the future of sports with iPS cells
FUNROOTS, I Peace, and Reju form a strategic alliance
FUNROOTS Co., Ltd. (Tokyo, Japan), I Peace, Inc. (California, USA), and Reju Inc. (Tokyo, Japan) entered a strategic partnership to integrate cutting-edge iPS cell technology into the sports industry, aiming to deliver innovative health management solutions, enhance athletic performance, and accelerate injury recovery, leveraging advancements in regenerative medicine. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 9
- Next Page »